144 related articles for article (PubMed ID: 9359746)
1. Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine.
Balzarini J; Pelemans H; Riess G; Roesner M; Winkler I; De Clercq E; Kleim JP
J Infect Dis; 1997 Nov; 176(5):1392-7. PubMed ID: 9359746
[TBL] [Abstract][Full Text] [Related]
2. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).
Balzarini J; Pelemans H; Riess G; Roesner M; Winkler I; De Clercq E; Kleim JP
Biochem Pharmacol; 1998 Mar; 55(5):617-25. PubMed ID: 9515572
[TBL] [Abstract][Full Text] [Related]
3. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure.
Rusconi S; De Pasquale MP; Milazzo L; Kurtagic S; Bulgheroni E; Citterio P; Galazzi M; La Seta Catamancio S; Galli M
Antivir Ther; 1998; 3(4):203-7. PubMed ID: 10682139
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activity of the human immunodeficiency virus type 1-specific nonnucleoside reverse transcriptase inhibitor HBY 097 alone and in combination with zidovudine in a phase II study. HBY 097/2001 Study Group.
Kleim JP; Winters M; Dunkler A; Suarez JR; Riess G; Winkler I; Balzarini J; Oette D; Merigan TC
J Infect Dis; 1999 Mar; 179(3):709-13. PubMed ID: 9952383
[TBL] [Abstract][Full Text] [Related]
5. Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model.
Stilianakis NI; Boucher CA; De Jong MD; Van Leeuwen R; Schuurman R; De Boer RJ
J Virol; 1997 Jan; 71(1):161-8. PubMed ID: 8985335
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype.
Van Laethem K; Witvrouw M; Pannecouque C; Van Remoortel B; Schmit JC; Esnouf R; Kleim JP; Balzarini J; Desmyter J; De Clercq E; Vandamme AM
AIDS; 2001 Mar; 15(5):553-61. PubMed ID: 11316991
[TBL] [Abstract][Full Text] [Related]
7. Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors.
Shafer RW; Winters MA; Iversen AK; Merigan TC
Antimicrob Agents Chemother; 1996 Dec; 40(12):2887-90. PubMed ID: 9124861
[TBL] [Abstract][Full Text] [Related]
8. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants.
Kleim JP; Rösner M; Winkler I; Paessens A; Kirsch R; Hsiou Y; Arnold E; Riess G
Proc Natl Acad Sci U S A; 1996 Jan; 93(1):34-8. PubMed ID: 8552634
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
[TBL] [Abstract][Full Text] [Related]
11. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
Mathiesen S; Dam E; Roge B; Joergensen LB; Laursen AL; Gerstoft J; Clavel F
Antivir Ther; 2007; 12(3):335-43. PubMed ID: 17591023
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication.
Kleim JP; Bender R; Kirsch R; Meichsner C; Paessens A; Rösner M; Rübsamen-Waigmann H; Kaiser R; Wichers M; Schneweis KE
Antimicrob Agents Chemother; 1995 Oct; 39(10):2253-7. PubMed ID: 8619578
[TBL] [Abstract][Full Text] [Related]
13. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
[TBL] [Abstract][Full Text] [Related]
14. Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1.
Diallo K; Oliveira M; Moisi D; Brenner B; Wainberg MA; Götte M
Antimicrob Agents Chemother; 2002 Jul; 46(7):2254-6. PubMed ID: 12069983
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates.
Duan C; Poticha D; Stoeckli TC; Petropoulos CJ; Whitcomb JM; McHenry CS; Kuritzkes DR
J Infect Dis; 2001 Nov; 184(10):1336-40. PubMed ID: 11679926
[TBL] [Abstract][Full Text] [Related]
16. Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy.
Kuritzkes DR; Shugarts D; Bakhtiari M; Poticha D; Johnson J; Rubin M; Gingeras TR; Kennedy M; Eron JJ
J Acquir Immune Defic Syndr; 2000 Jan; 23(1):26-34. PubMed ID: 10708053
[TBL] [Abstract][Full Text] [Related]
17. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
[TBL] [Abstract][Full Text] [Related]
19. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
[TBL] [Abstract][Full Text] [Related]
20. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.
Das K; Sarafianos SG; Clark AD; Boyer PL; Hughes SH; Arnold E
J Mol Biol; 2007 Jan; 365(1):77-89. PubMed ID: 17056061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
